Two primitive neuroectodermal tumor cell lines require an activated insulin-like growth factor I receptor for growth in vitro.
OBJECTIVE
To determine the expression of the insulin-like growth factors (IGFs) and the IGF-I receptor in primitive neuroectodermal tumor cell lines and to assess the importance of these proteins in the growth of cell lines in vitro.


METHODS
Ribonucleic acid blotting and reverse transcriptase-polymerase chain reaction were used for detection of IGF and IGF-I expression. Ribonucleic acid blotting was used for detection of up-regulation of c-fos in the presence of exogenous growth factor. Immunoprecipitation was used to demonstrate autophosphorylation of the receptor in the presence of exogenous growth factor. Ligand binding analysis was used to determine the binding affinity of the receptor and the number of receptors per cell. Growth of curves in the presence of monoclonal antibody that blocks binding of ligand to receptor was measured to determine the requirement for an activated receptor during growth.


RESULTS
Expression of IGF-II was identified in one cell line. No expression of IGF-I was seen in any cell line. Expression of IGF-I receptor was detected in all three cell lines. Immunoprecipitation experiments demonstrated autophosphorylation of the receptor after addition of IGF-I to growing cells. Ligand binding analysis revealed 9.2 x 10(4) and 4 x 10(4) receptors per cell in the Daoy and PFSK cell lines, respectively. Addition of either IGF alone or in combination to serum-starved cells was not able to restore growth of the cell lines. A blocking monoclonal antireceptor antibody decreased growth of Daoy and PFSK cells in a dose-dependent fashion. Complete arrest of growth occurred at 1 microgram/ml antibody in both cell lines.


CONCLUSIONS
The IGF-I receptor is expressed by primitive neuroectodermal tumor cell lines in vitro. An activated receptor is important for cell proliferation in vitro. Additional work will establish the importance of these findings for tumors in vivo.
Chin
L S
LS
Division of Neurosurgery, University of Maryland School of Medicine, Baltimore, USA.
Yung
W K
WK
Raffel
C
C
D000906:Antibodies / Q000276:immunology; D001790:Blood Physiological Phenomena; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology*; D002455:Cell Division; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism* / Q000502:physiology; D007335:Insulin-Like Growth Factor II / Q000502:physiology; D008024:Ligands; D018242:Neuroectodermal Tumors, Primitive / Q000378:metabolism* / Q000473:pathology*; D010766:Phosphorylation; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D017451:Receptors, Somatomedin / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D013002:Somatomedins / Q000378:metabolism / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000906:Antibodies; D008024:Ligands; D016760:Proto-Oncogene Proteins c-fos; D017451:Receptors, Somatomedin; D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II